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Cervical cancerWehave reported previously that LIM homeobox transcription factor 1α (LMX1A) is hypermethylated and func-
tions as a metastasis suppressor in cervical cancer cells. However, the regulation of LMX1A in carcinogenesis has
not been reported.We aim to clarifywhether speciﬁcity protein 1 (Sp1) and enhancer of zeste homolog 2 (EZH2)
are involved in the regulation of LMX1A in cervical cancer. First we characterized the LMX1A promoter and used
overexpression, knockdown, and reporter assays to show that Sp1 increased LMX1A promoter activity. Next, we
used site-directed mutagenesis and electrophoresis mobility shift assays (EMSAs) to demonstrate that Sp1-
binding sites were important for Sp1-mediated activation of the LMX1A promoter. Chromatin immunoprecipita-
tion data demonstrated that Sp1 could bind directly to the LMX1A promoter and activate endogenous LMX1A ex-
pression in cells pretreated with 5-aza-2′-deoxycytidine (5-aza-dC). Knockdown of EZH2 decreased H3K27me3
histone modiﬁcation but was insufﬁcient to restore LMX1A expression. To explore the effect of EZH2 on the en-
dogenous LMX1A promoter, we treated EZH2-knockdown cells with 5-aza-dC and trichostatin A (TSA) and
then depleted the cells of drugs for 3 days. H3K14ac was enriched at the LMX1A promoter in EZH2-
knockdown cells and LMX1AmRNA was still expressed. Taken together, these data imply that Sp1 may activate
LMX1A expression upon oncogenic stress during cervical cancer development. Moreover, suppression of EZH2
may delay resilencing of LMX1A after the removal of 5-aza-dC and TSA.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
High-risk speciﬁc types of human papillomavirus (HPV) are associ-
ated with cervical cancer progression in humans [1]. The transforming
potential of oncogenic HPVs is closely related to the viral E6 and E7
oncoproteins, which inactivate p53 and retinoblastoma proteins (Rb)
[2]. Extensive studies have shown that expression of the viral oncogene
is essential but not sufﬁcient for cancer development. Many reports
have demonstrated that both genetic changes and epigenetic modiﬁca-
tions play important roles in complex signaling pathways in cervical
carcinogenesis [3–5].
Loss of function and gain of function through genetic alterations,
such as mutations, deletions, copy-number aberrations, and chromo-
somal rearrangements, are associated with cancer progression [6]. In
addition, epigenetic mechanisms that modify chromatin structure, in-
cludingDNAmethylation, covalent histonemodiﬁcations, incorporation
of histone variants, nucleosome remodeling, and noncoding RNAs, areInstitute of Microbiology and
ection 6, Min-Chuan East Road,
fax: +886 2 87917654.
dmctsgh.edu.tw (Y.-W. Lin).
ights reserved.also involved in carcinogenesis. Covalent histone modiﬁcations are
posttranslational modiﬁcations of histone proteins mediated by en-
zymes that can modify covalent attachments at speciﬁc residues. In
many cancers, dysregulation of epigenetic modiﬁcations, such as pro-
moter hypermethylation and chromatin condensation, can lead to the
activation of oncogenes and silencing of tumor suppressors [7–9].
Enhancer of zeste homolog 2 (EZH2), one of the histone
methyltransferases (HMTs), encodes the catalytic subunit of the
polycomb repressive complex 2 (PRC2). EZH2 contains the signature
SET domain, which methylates lysine 27 of histone H3 (H3-K27), as a
repressive marker. EZH2 and H3-K27 methylation are implicated in
mammalian X chromosome inactivation and germline silencing [10].
Moreover, high EZH2 expression correlates strongly with cellular trans-
formation, tumor progression, and poor prognosis [11–15]. Silencing
EZH2 expression leads to reexpression of tumor suppressor genes by
decreasing the content of trimethylated histone 3K27 (H3K27me3) in
many cancer cell lines [16–18]. Some studies have also shown that
EZH2 can physically interact with the DNA methyltransferases
(DNMTs), facilitate their binding to EZH2-target promoters, and affect
the DNA methylation level of the target genes of EZH2 [19,20]. Aberra-
tions in DNA methylation and histone modiﬁcation are also observed
in the promoter region of genes and may inactivate tumor suppressor
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enhance DNMT1 expression through repression of p53 [25]. Further-
more, EZH2 expression is activated by HPV16 E7 at the transcriptional
level via E7-mediated release of E2F from pocket proteins [26]. EZH2
is signiﬁcantly upregulated in cervical cancer tissues, and knockdown
of EZH2 can inhibit colony formation and invasion ability [26,27]. More-
over, CDH1 (E-cadherin), regulated by EZH2, has been linked to cancer
invasion and metastasis [28,29]. Taken together, we suggest that EZH2
plays important roles in tumor progression in cervical cancer.
In our previous study, we have characterized a gene, LIM homeobox
transcription factor 1α (LMX1A), which is hypermethylated in squa-
mous cell carcinomas (SCC) and functions as a metastasis suppressor
in cervical cancer [21,30]. The expression of LMX1A protein is low in
normal parts of the cervical epithelium but is high in cervical
intraepithelial neoplasia (CIN) and carcinoma in situ (CIS), and is re-
duced markedly in invasive and metastatic cancer cells [30]. The speci-
ﬁcity protein 1 (Sp1) protein expression pattern is similar to that of
LMX1A in cervical cancer [31]. Sp1 belongs to the speciﬁcity protein/
Krüppel-like factor (Sp/KLF) transcription factor family, which interacts
with the GC-rich (5′-GGGGCGGGG-3′) motif in promoters. The DNA
binding domain of Sp1 comprises three adjacent zinc ﬁngers of the clas-
sical Cys2–His2 type, is expressed ubiquitously in many tissues, and is
involved in multiple signal pathways [32,33]. Overexpression of Sp1
can have positive or negative effects on cell growth [34]. Sp1 has been
implicated in invasion, metastasis, proliferation, and oncogenesis, and
has antitumor activities [34–37]. These ﬁndings lead us to postulate
that there might be a link between LMX1A and Sp1 in the development
of SCC.
LMX1A is one of the LIM homeobox-containing genes and plays an
important role during development. More recently, LMX1A has been re-
ported as a metastasis suppressor or tumor suppressor. However, the
regulation of LMX1A in carcinogenesis remains unclear. Therefore, we
want to clarify the mechanisms responsible for the regulation of
LMX1A in cervical cancer. Because the role of Sp1 in cellular transforma-
tion is contradictory, and several predicted Sp1 sites are located in the
LMX1A promoter region, we propose that Sp1 can modulate LMX1A ex-
pression in cervical cancer. Moreover, the EZH2 expression pattern is
highly associated with tumor cell invasion in cervical cancer. Our pre-
liminary data showed that overexpression of EZH2 could repress
LMX1A expression in cancer cells (Huh7). This suggests that EZH2
might be also involved in the regulation of LMX1A. In this study, we
found that Sp1 bound directly to the LMX1A promoter and activated en-
dogenous LMX1A expression when the methylation level of promoter
was low. We also found that EZH2 could regulate LMX1A expression
through modiﬁcation of chromatin status.
2. Materials and methods
2.1. Cell culture
HeLa, HeLa3rd, SiHa, CaSki, C33A human cervical cancer cell lines,
and Huh7 human hepatocellular carcinoma (HCC) cell line were cul-
tured in Dulbecco's modiﬁed Eagle's medium (DMEM) or RPMI 1640
supplementedwith 10% (w/v) fetal bovine serum (Invitrogen, Carlsbad,
CA, USA), penicillin at 100 U/ml, streptomycin at 100 μg/ml and L-
glutamine at 2 mmol/l (Gibco BRL, Grand Island, NY, USA). HeLa3rd sub-
linewas generated according to previous study [30]. HPV-immortalized
cervical epithelial cells (Z172 and Z183A) were cultured in DMEMwith
10% (w/v) Nu-Serum (BD Bioscience, San Jose, CA, USA) and hydrocor-
tisone at 50 ng/ml (Sigma-Aldrich, St. Louis, MO, USA).
2.2. Transfection and Sp1 and EZH2 overexpression
Cells were seeded in 24-well plates at 80%–90% conﬂuence and then
transfectedwith various amounts of pCDNA3.1-Sp1-V5 (NM_138473.2)
and pCDNA3-3myc-EZH2 (a gift from Dr. Cha's laboratory [38]). Theseexpression plasmids and vector controls were transfected with the
Lipofectamine™ 2000 (Invitrogen) according to the manufacturer's
instruction.2.3. Knockdown of Sp1 and EZH2 by RNA interference
Cells were transfected with plasmid containing short hairpin RNAs
(shRNAs) of human Sp1 that were obtained from the National RNAi
Core Facility located at the Institute of Molecular Biology/Genomic
Research Center, Academia Sinica, Taiwan. The target sequences for
human Sp1 shRNA #1 and shRNA #2 were 5′-CCCAAGTTTATTT
CTCTCTTA-3′ (TRCN0000020444) and 5′-GGCAGATCTGCAGTCCAT
TAA-3′ (TRCN0000274153), respectively. A plasmid containing scram-
bled shRNA (LacZ) that targeted non-speciﬁc sequencing at 5′-
TGTTCGCATTATCCGAACCAT-3′ (TRCN0000072223) was used as a neg-
ative control. In addition, short hairpin RNAs (shRNAs) of human EZH2
(GenBank: NM_004456) were purchased from Thermo Fisher Scientiﬁc
(MA, USA). The target sequences of human EZH2 shRNA #1 and shRNA
#2 were 5′-GAAAGAACGGAAATCTTAA-3′ (V2LHS_238994) and 5′-
GAGGATCACCGAGATGATA-3′ (V2LHS_63068), respectively. A plasmid
containing scrambled shRNA was used as a negative control.2.4. Construction of Sp1 expression vector and LMX1A promoter
Human Sp1 cDNA clone (BC062539.1) was purchased from Thermo
Fisher Scientiﬁc (MA, USA). Sp1 cDNAwas generated by PCRwith prim-
er sets (Sp1+101-BamHIforward 5′-CTCGGATCCAGCGACCAAGATC
ACTC-3′ and Sp1+2437-XhoIreverse 5′-ACTCGAGTCAGAAGCCATTG
CCACTG-3′) and constructed into a shuttle yT&A cloning vector
(Yeastern Biotech Co., Ltd., Taipei, Taiwan). Created yT&A-Sp1 plasmid
was digested with BamHI and XhoI and then cloned into pCDNA3.1-
V5 vector (Invitrogen) to generate pCDNA3.1-Sp1-V5 construct. The
human LMX1A promoter (−1458/+221) was ampliﬁed by PCR with
primer sets (LMX1A−1458 forward 5′-GAGTCCCATGGCCTCTGTAC-3′
and LMX1A+221 reverse 5′-GTTCGGGCCGGGCCGG-3′). The PCR prod-
uct was constructed into a shuttle yT&A cloning vector. Created yT&A-
LMX1A-p−1458/+221 plasmid was digested with KpnIand BglII and
then cloned into pGL4.21 basic vector (Promega, Madison, WI, USA) to
generate pGL4.21-LMX1A-p−1458/+221 construct.2.5. Deletion and site-directed mutagenesis of the LMX1A promoter
Different deletion constructs of the LMX1A promoter were ampliﬁed
by PCRwith the same reverse primer LMX1A+221 and speciﬁc forward
primer sets: 5′-CACGGGACGCGCTGCC-3′ for the LMX1A-p−1016/
+221; 5′-CTCCGCAACTTCTCTCTGCT-3′ for the LMX1A-p−624/+221;
5′-GTATAGGTTGGGGCGGAGTC-3′ for the LMX1A-p−133/+221; 5′-
GCAGGAGAAGGAGAAACGCAG-3′ for the LMX1A-p−62/+221, re-
spectively. These PCR products were cloned into shuttle yT&A cloning
vectors. Generated yT&A-LMX1A-promoter constructs were digested
with KpnI and BglII and then constructed into pGL4.21 basic vector
(Promega). The mutant constructs of LMX1A reporters were generated
from yT&A-LMX1A-p−133/+221 plasmid using the Finnzymes
Phusion® Hot Start High-Fidelity DNA Polymerase (Thermo Fisher Sci-
entiﬁc Inc., MA, USA) and mutant primers. Mutagenesis primers were
as follows: Mut-Sp1-2F, forward, 5′-GTATAGGTTGTGTCTGAGTCGG
ATTC-3′ and complement strand Mut-Sp1-2R, 5′-CCGAATCCGACTC
AGACACAACCTATACGA-3′; Mut-Sp1-1F, forward 5′-ACGCAGTTGTGT
GTCGTAGGCCTAAGTAC-3′ and complement strand Mut-Sp1-1R, 5′-
GTACTTAGGCCTACGACACACAACTGCGTT-3′. Generated mutant yT&A-
LMX1A-p−133/+221 constructs were digested with KpnI and BglII
and then cloned into pGL4.21 basic vector (Promega) to establish the
mutant LMX1A reporter.
Fig. 1. Identiﬁcation and functional analysis of the LMX1A promoter. (A) Nucleotide sequence of the 5′-ﬂanking region of the human LMX1A gene is shown. The human LMX1A promoter is
analyzed using the TFSEARCH searching tool. Eight putative binding sites of the Sp1 transcription factor are underlined and six putative E-box binding elements are indicated with gray
highlight. The arrow indicates the transcription start site (TSS). (B) Schematic diagram of Sp1 binding elements in the human LMX1A promoter and deletion mapping of the LMX1A pro-
moter. Different truncated forms were constructed with pGL4.21. (C) Promoter activity was analyzed by dual luciferase assay after cells were cotransfected for 48 h with different
pGL4.21–LMX1A promoters and the phRL-TK plasmid. All experiments were performed at least three times.
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Cells were seeded on 24-well plates at 90% conﬂuence (HeLa, C33A
and HeLa3rd, 2 × 105 cells/well; SiHa, 2.5 × 105 cells/well), cultured
for 16 h and then cotransfected with 1 μg of reporter plasmids and
20 ng of phRL-TK plasmid (Promega) using Lipofectamine 2000. The
ratio of the DNA amounts for luciferase reporter constructs versus
phRL-TK plasmid was 50:1. To study the role of Sp1, cells were
cotransfected with LMX1A reporter plasmid, phRL-TK plasmid and dif-
ferent doses of pCDNA3.1-Sp1-V5 plasmid or Sp1 shRNA plasmid. After
48 h, the ﬁreﬂy luciferase activity of the cells were measured by a
Dual-luciferase reporter assay system (Promega). Renilla luciferaseactivity was used to normalize the transfection efﬁciency. In addition,
cells were cotransfected with 1 μg of reporter constructs, DNA and
20 ng of phRL-TK plasmid, 24 h later, and culturemediumwas replaced
with Mithramycin A (Sigma-Aldrich Co. LLC, Louis, USA) and incubated
for 24 h. Promoter activity was measured by the dual luciferase assay.
2.7. RNA extraction, cDNA synthesis and quantitative RT-PCR (qRT-PCR)
Total RNA was isolated by RNeasy Mini Kit (Qiagen, Valencia, USA).
Complementary DNA (cDNA) was synthesized by SuperScript™ III Re-
verse Transcriptase (Invitrogen). RT-PCRswere performed by PCRMas-
ter Mix Reagents Kit (Applied Biosystems, Foster City, CA, USA). qRT-
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Fig. 2. Sp1 increases LMX1A promoter activity in cervical cancer cell lines. (A) HeLa3rd and SiHa cells were transiently cotransfected with the LMX1A-p−133/+221 construct, phRL-TK
plasmid and different doses of pcDNA3.1-Sp1-V5. LMX1A promoter activity wasmeasured after 48 h by dual luciferase assay. The protein expression level of the exogenous Sp1wasmea-
sured byWestern blot analysis. (B) Cells were transfectedwith LMX1A-p−133/+221 and treatedwith different doses of mithramycin A (MTM), and the promoter activity of LMX1A-p−
133/+221 wasmeasured by dual luciferase assay. The inhibitory effect of MTM on endogenous Sp1 protein level wasmeasured byWestern blot analysis. (C) HeLa3rd and SiHa cells were
transiently cotransfectedwith the LMX1A-p−133/+221 construct and Sp1 shRNAs (shRNA Sp1 #1, shRNA Sp1 #2) or vector control for 48 h. Promoter activitywasmeasured by the dual
luciferase assay. The inhibitory effect of shRNAs on endogenous Sp1 protein was measured by Western blot analysis. The numbers in the blot represent the ratios between Sp1 and the
internal control. All measurementswere obtained in triplicate in at least three independent experiments. Values are expressed as themean ± SEM (*p b 0.05, **p b 0.01, Student's t test).
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and analyzed by Roche LightCycler ® 480 systems (Roche, Indianapolis,
IN, USA). Primer pairs used in q-PCR were as follows: LMX1A, forward
5′-TCAGAAGGGTGATGAGTTTGTCC-3′ and reverse 5′-GGGGCGCTTATG
GTCCTTG-3′; CDH1, forward 5′-GCCGCCATCGCTTACACCATC-3′ and re-
verse 5′-GTGGTGGGATTGAAGATCGGAGG-3′; EZH2, forward 5′-AAT
CAGAGTACATGCGACTGAGA-3′ and reverse 5′-GCTGTATCCTTCGCTG
TTTCC-3′; Sp1, forward 5′-GGGCAATGGTAATGGTGGTGGTG-3′ andFig. 3. Sp1 binding sites are important for Sp1-mediated activation of LMX1A gene transcription.
positions of the Sp1 binding sites. Single or double mutations of Sp1 binding sites (−124/−11
mutant promoter constructs in the pGL4.21 vector. Promoter activity wasmeasured by the dua
pcDNA3.1-Sp1-V5 and LMX1A–p−133/+221 or mutant (Sp1-1m, Sp1-2m, or Sp1-1/2m) fo
obtained from at least three independent experiments. Values are expressed as the mean ±
were prepared from SiHa cells and incubated with biotin-labeled LMX1A-Sp1 probes (100 nM
of “hot mut probe”; lanes 3 and 9). Binding speciﬁcity was evaluated by competition with a 100
of the biotin-labeled Sp1 probes (hot probes) to themixture (lanes 4, 5, 10, and 11). For the supe
before addition of the biotin-labeled Sp1 probe (hot probe) to the mixture (lanes 6 and 12).reverse 5′-GGTAGCCCCAGAGGAGGAAGAG-3′; GAPDH, forward 5′-
ACCCACTCCTCCACCTTTGACG-3′ and reverse 5′-TCTCTTCCTCTTGTGC
TCTTG-3′.
2.8. Western blot analysis
Cells were harvested and lyzed by RIPA lysis buffer (Thermo). The
concentration of proteinwasmeasured by the BCA kit (Pierce, Rockford,(A) Schematic representation of the LMX1A promoter andmutant constructs indicating the
6 and−39/−28) are shown on the left. Cells were transiently transfected with control or
l luciferase assay after 48 h. (B) HeLa3rd and SiHa cells were transiently cotransfected with
r 48 h. Promoter activity was measured using the dual luciferase assay. All values were
SEM (*p b 0.05, **p b 0.01, ***p b 0.0001, Student's t test). (C). Nuclear extracts (5 μg)
of “hot probe”, Sp1-1 and Sp1-2; lanes 2 and 8) or biotin-labeled Sp1m probes (100 nM
-fold excess of thewild-type cold probe or its mutant cold probe for 5 min before addition
rshift assays, nuclear extractswere preincubatedwith anti-Sp1 antibody at 4 °C for 30 min
Fig. 4. Inhibition of Sp1 suppresses the reexpression of LMX1A after 5-aza-dC treatment in cervical cancer cells. (A) HeLa3rd and SiHa cells were treated with or without 5′-aza-2′-
deoxycytidine (5-aza-dC) for 4 days. The same cells were then treated with or without mithramycin A (MTM) for 24 h. LMX1A mRNA expression was measured by RT-PCR and qRT-
PCR. (B) The inhibitory effect of MTM on endogenous Sp1 mRNA expression was estimated by qRT-PCR. Values are expressed as mean ± SEM (**p b 0.01, *p b 0.05, Student's t test).
(C, D) HeLa3rd cells were treated with or without 5-aza-dC for 4 days, and the expression of the target mRNA was measured by RT-PCR. A chromatin immunoprecipitation (ChIP)
assaywas performed using anti-Sp1 and anti-H3K27me3. (C) Inset: RT-PCR analysis of the endogenous expression of LMX1AmRNA. The immunoprecipitated genomicDNAwas ampliﬁed
with the speciﬁc primers (LMX1A−133F/+1R) at the LMX1A promoter containing both the Sp1-2 and Sp1-1 sites. (D) Inset: RT-PCR analysis of the endogens expression of CDH1mRNA.
CDH1mRNA levelwas 1.9-fold higher in cells treatedwith 5-aza-dC comparedwith the control cells. The immunoprecipitated genomicDNAwas ampliﬁedwith the speciﬁc primers (CDH1
−173F/+30R) for the CDH1 promoter containing the ﬁve Sp1 sites.
3211W.-C. Lin et al. / Biochimica et Biophysica Acta 1833 (2013) 3206–3217IL, CA). Equal amounts of protein samples were separated on 12% sodi-
um dodecyl sulfate (SDS)-polyacrylamide gels and then transferred to
PVDF membranes. Primary antibodies used for Western blotting were
as follows; anti-V5 (Invitrogen™ Life Technologies, cat: R960), anti-
Sp1 (Millipore Corporation, Billerica, MA, USA, cat: #07-645), anti-
H3K27me3 (Millipore, cat: #07-499), anti-H3 (Millipore, cat: #06-
755) and anti-EZH2 (Cell Signaling, MA, USA, cat: #3147).2.9. Electrophoresis mobility shift assay (EMSA)
EMSAswere performed by EMSAGel Shift Kit (Affymetrix Panomics,
Santa Clara, CA, USA) according to the manufacturer's instruction. Nu-
clear protein was extracted from SiHa cancer cells by NE-PER Nuclear
and Cytoplasmic Extraction Reagents Kit (Thermo). Oligonucleotides
were labeled with biotin using Biotin 3′-OH end DNA Labeling Kit
3212 W.-C. Lin et al. / Biochimica et Biophysica Acta 1833 (2013) 3206–3217(Thermo). Speciﬁc oligonucleotides were used to generate wild type
Sp1 and mutant Sp1 probe. Oligonucleotide sequences are as follows:
wild type Sp1-1 probe (5′-ACGCAGTTGGGGGGCGGAGGCCTAAGTAC-3′, 5′-GTACTTAGGCCTCCGCCCCCCAACTGCGT-3′); mutant Sp1-1 probe
(5′-ACGCAGTTGTGTGTCGTAGGCCTAAGTAC-3′, 5′-GTACTTAGGCCTAC
GACACACAACTGCGT-3′); wild type Sp1-2 probe (5′-TCGTATAGGTT
3213W.-C. Lin et al. / Biochimica et Biophysica Acta 1833 (2013) 3206–3217GGGGCGGAGTCGGATTCGG-3′, 5′-CCGAATCCGACTCCGCCCCAACCTATA
CGA-3′); mutant Sp1-2 probe (5′-TCGTATAGGTTGTGTCTGAGTCG
GATTCGG-3′; 5′-CCGAATCCGACTCAGACACAACCTATACGA-3′).
2.10. Demethylation treatment, bisulﬁte conversion and bisulﬁte sequencing
Cells were treatedwith DMSO or 5-aza-2′-deoxycytidine (5-aza-dC)
and combined with or without TSA, a histone deacetylase (HDAC) in-
hibitor (Sigma) leading to the demethylation and reexpression of
genes. DNA was isolated and performed for further studies. Bisulﬁte
modiﬁcation was accomplished by a CpGenome Fast DNA Modiﬁcation
Kit (Millipore, Bedford,MA, USA). Bisulﬁte-modiﬁedDNAwas ampliﬁed
by PCR using two primer sets (forward 5′-TATAGTGTTTTTTTTCG
ATTTGGGGTAGGT-3′; reverse 5′-CAAAATCAACCAAAAAAATAAAATCCA
ACC-3′ and forward 5′-TAGTTATTGGGAGAGAGTTYGTTTATTAG-3′; re-
verse 5′-CTACCCCAAATCRAAAAAAAACAC-3′). These PCR products
were ampliﬁed and cloned into the yT&A vector for sequencing.
2.11. Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assayswere performedusing
EZ-Magna ChIP A/G Chromatin Immunoprecipitation Kit (Millipore Cor-
poration, Billerica, MA, USA) and the detail procedureswere according to
the manufacturer's protocol.
All antibodies were used for ChIP, including anti-Sp1 (Millipore, cat.
#07-645), anti-H3K14ac (Millipore, cat. #06599), anti-H3ac (Millipore,
cat. #06-598), anti-H3K9ac (Millipore, cat. #07352), anti-H3K27me3
(Abcam, ab6002), anti-H3K9me3 (Abcam, ab8898), DNMT1 (Abcam,
ab13537), DNMT3b (Abcam, ab13604) and anti-mouse IgG (Millipore,
cat. #12-371B). Immunoprecipitated DNA and input were ampliﬁed
by q-PCR with speciﬁc primers; LMX1A promoter primers, forward 5′-
GTATAGGTTGGGGCGGAGTC-3′ and reverse 5′-TTGAAGTCAACACGTTA
TGTACTTAGGC-3′; CDH1 promoter primers, forward 5′-TAGAGGG
TCACCGCGTCTAT-3′ and reverse 5′-TCACAGGTGCTTTGCAGTTC-3′.
2.12. Statistical analysis
GraphPad Prism4 for Windows (GraphPad Software, Inc., CA, USA)
was performed to analyze the data. All values are expressed as
mean ± SEM. The Student's t-test and Mann–Whitney were used to
compare promoter activity and relative RNA expression in the cervical
cell lines and stable transfectants.
3. Results
3.1. Identiﬁcation and functional analysis of the LMX1A promoter
To understand the transcriptional regulation of LMX1A (GenBank ac-
cession number NM_177398.2), we ﬁrst cloned and analyzed 1.5 kb of
human genomic DNA upstream to the transcription start site (TSS) of
the LMX1A gene. Using the TFSEARCH website (http://www.cbrc.jp/
research/db/TFSEARCH.html), we discovered eight putative binding
sites of the Sp1 transcription factor in the promoter of the LMX1A
gene, two of them located close to the TSS (Fig. 1A). To further charac-
terize the functional promoter region of LMX1A, we created a set ofFig. 5. Knockdown of EZH2 decreases the level of H3K27me3 but does not restore LMX1A exp
measured by qRT-PCR andWestern blot analysis in the shRNA-EZH2 transfectant and negative
below the blot represent the ratios between the EZH2 transfectant and internal control. (B) Ch
H3K27me3 and anti-H3K9me3 in shRNA-EZH2 stable clones and control. The immunoprecipita
of H3K27me3 was reduced in shRNA-EZH2 stable cells compared with the control cells. (C) LM
clones and control cells. The stable LMX1A transfectant was used as a positive control. (D) The
control cells was analyzed by bisulﬁte sequencing. Each circle denoted a CpG site; solid circles r
indicate the methylation frequencies. (E) Chromatin immunoprecipitation analysis of the LMX
The immunoprecipitated genomicDNAwas ampliﬁedwith the speciﬁc primers (LMX1A−133F/
with the control cells.luciferase reporter vectors (pGL4.21) that contained different truncated
DNA fragments (Fig. 1B). The luciferase reporter assay was then used to
evaluate the basal promoter activity of LMX1A. The results showed that
the LMX1A-p−133/+221 promoter containing two putative Sp1 bind-
ing sites had the strongest transcriptional activity in cervical cancer cell
lines (Fig. 1C). The LMX1A-p−133/+221 promoter was used for fur-
ther studies of LMX1A promoter activity.
3.2. Sp1 increases the promoter activity of LMX1A in cervical cancer cell
lines
To further study the role of Sp1 in LMX1A promoter activity, we ﬁrst
checked themRNAexpression level of Sp1 in theHPV-immortalized cer-
vical epithelial cells (Z172 and Z183A) and cervical cancer cell lines
(HeLa, HeLa 3rd, SiHa and CaSki). High expression level of Sp1 was de-
tected in immortalized cervical epithelial cells and cervical cancer cell
lines (Supplementary Fig. S1A). We then cotransfected cervical cancer
cell lines with different doses of pCDNA3.1-Sp1-V5 plasmid and the
LMX1A promoter construct (LMX1A-p−133/+221). Exogenous Sp1 in-
creased the transcriptional ability of the LMX1A promoter in a dose-
dependent manner, as measured with a luciferase assay in HeLa3rd
and SiHa cells (Fig. 2A). Inhibition of endogenous Sp1 expression by
mithramycin A (MTM), a Sp1-speciﬁc inhibitor [39], decreased the tran-
scriptional activity of the LMX1A promoter (LMX1A-p−133/+221)
(Fig. 2B, upper). Knockdown of Sp1 using shRNAs resulted in suppres-
sion of LMX1A promoter activity in HeLa3rd and SiHa cells (Fig. 2C,
upper). The knockdown efﬁciency of Sp1 protein and the mRNA level
were conﬁrmed by Western blot analysis (Fig. 2B and C, lower) and
qRT-PCR (Supplementary Fig. S2A and S2B). These data suggest that
Sp1 functions as a positive regulator of the LMX1A promoter.
3.3. Sp1 binding sites are important for Sp1-mediated activation of LMX1A
gene transcription
We constructed three mutants (Sp1-1m, Sp1-2m, and Sp1-1/2m)
using site-directed mutagenesis to evaluate the role of two consensus
Sp1 binding sites at −124/−116 bp (Sp1-2) and −39/−28 bp (Sp1-
1) in the LMX1A-p−133/+221 promoter. Mutation of individual sites
(Sp1-2m or Sp1-1m) and two sites (Sp1-1/2m) in the LMX1A promoter
decreased the promoter activity of these mutants compared with the
activity in wild-type in HeLa3rd, SiHa, HeLa and C33A cells (Fig. 3A and
Supplementary Fig. S3). These data suggest that both of these Sp1 bind-
ing sites are crucial in the proximal promoter (LMX1A-p−133/+221).
Next, we cotransfected Sp1 and mutant LMX1A promoter constructs
(Sp1-2m, Sp1-1m, or Sp1-1/2m) into cervical cancer cells to evaluate
whether Sp1 sites are vital for Sp1-mediated activation of LMX1A pro-
moter activity. The promoter activity in the mutant group was signiﬁ-
cantly decreased compared with the wild type (Fig. 3B). We also used
a gel electrophoresis mobility shift assay (EMSA) to check whether
Sp1 can regulate LMX1A promoter activity directly. Biotin-labeled oligo-
nucleotides (“hot probes”) containing the putative Sp1-2 or Sp1-1 bind-
ing sites of LMX1Awere incubated with nuclear extract containing Sp1
protein. The EMSA results showed that Sp1 transcription factors could
bind to the LMX1A-Sp1-1 and LMX1A-Sp1-2 probes. The arrows in
Fig. 3C indicate Sp1 binding but others were nonspeciﬁc bindingression in cervical cancer cell lines. (A) The inhibition efﬁciency of EZH2 knockdown was
control (upper). The H3K27me3 level was analyzed byWestern blot (lower). The numbers
romatin immunoprecipitation analysis of the LMX1A promoter was performed using anti-
ted genomic DNAwas ampliﬁedwith the speciﬁc primers (LMX1A−133F/+1R). The level
X1AmRNA expression level was measured by RT-PCR and qRT-PCR in shRNA-EZH2 stable
methylation level of the LMX1A promoter (−315/+94) in shRNA-EZH2 stable clones and
epresent methylated sites and open circles represent unmethylated sites. The percentages
1A promoter was performed using anti-DNMT1 in shRNA-EZH2 stable clones and control.
+1R). The binding level of DNMT1was not changed in shRNA-EZH2 stable cells compared
Fig. 6. Suppression of EZH2may delay the resilencing of LMX1A after removal of DNMT andHDAC inhibitors. (A) Cells were treatedwith the DNA demethylation agent 5-aza-dC for 4 days
and with the HDAC inhibitor (trichostatin A, TSA) for 1 day to restore LMX1A expression. The cells were then depleted of the drugs and cultured for 3 more days. LMX1A expression was
analyzed by RT-PCR after removal of the drugs in HeLa3rd shRNA-EZH2 #1 stable cones and control cells. Semiquantitative RT-PCR data are also shown in the right panel. (B) Chromatin
immunoprecipitation analysis of the LMX1A promoter was performed with the corresponding antibody. The immunoprecipitated genomic DNA was ampliﬁed with the speciﬁc primer
LMX1A−133F/+1R in EZH2 shRNA-EZH2 #1 stable clones and control cells under different conditions.
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LMX1A-Sp1-2 or LMX1A-Sp1-1 wild-type oligonucleotide (“cold
probes”) abolished Sp1 protein binding to the hot probes and reduced
the nonspeciﬁc binding (Fig. 3C, lane 2 versus lane 4 and lane 8 versus
lane 10). By contrast, 100-fold excess of unlabeled LMX1A-Sp1-1 or
LMX1A-Sp1-2mutant competitors (“coldmut probes”) had no inhibito-
ry effects on Sp1 binding to the hot probes (lane 2 versus lane 5 and lane
8 versus lane 11). Moreover, preincubation of nuclear extracts with an-
tibody speciﬁc to Sp1 decreased Sp1 binding to the hot probes (lanes 6
and 12). These data suggest that both of the Sp1 binding sites in the
LMX1A promoter are important for Sp1 binding and activation of
LMX1A expression.
3.4. Inhibition of Sp1 suppresses reexpression of LMX1A in cervical cancer
cells after 5-aza-dC treatment
Next, we determined whether Sp1 can activate endogenous LMX1A
expression in cervical cancer cell lines. The promoter regions of LMX1A
are hypermethylated [21,30], and LMX1A expression has not been de-
tected in all available cervical cancer cell lines and immortalized cervical
epithelial cells (Supplementary Fig. S1B). Hence, we ﬁrst used 5-aza-dC,
a DNMT inhibitor, to restore LMX1A expression and demethylation of
the LMX1A promoter (Fig. 4A and Supplementary Fig. S4A). We then
checked whether Sp1 is necessary for LMX1A reexpression by treating
5-aza-dC-treated-cells with the Sp1 inhibitor, MTM. The protein and
RNA levels of Sp1 did not change after treatment with 5-aza-dC
(Fig. 4B and Supplementary Fig. S4B). These results show that inhibition
of Sp1 diminishes the reexpression of LMX1A in 5-aza-dC-treated cervi-
cal cancer cells (Fig. 4A and B). A chromatin immunoprecipitation
(ChIP) assay conﬁrmed the increased binding of Sp1 to the LMX1A pro-
moter after 5-aza-dC treatment. Interestingly, H3K27me3, a repressive
histone marker, was enriched in the LMX1A promoter but its content
did not change after 5-aza-dC treatment (Fig. 4C). E-cadherin (CDH1),
known to increase after 5-aza-dC treatment and regulated by Sp1
[40,41], was used as an experiment control (Fig. 4D). To further prove
Sp1 could enhance endogenous LMX1A expression, we overexpressed
Sp1 in Huh7 cells, a hepatocellular carcinoma cell line with detectable
LMX1A expression (Supplementary Fig. S1B). Overexpression of Sp1 in-
creased the transcription of LMX1A in a dose-dependent manner (Sup-
plementary Fig. S5A, left). Inhibition of Sp1 using MTM, a Sp1
inhibitor, could repress LMX1A expression in a dose-dependentmanner
(Supplementary Fig. S5A, right). Chromatin immunoprecipitation
(ChIP) assay demonstrated the enriched binding of Sp1, H4ac and
H3K9ac histone activation markers to the LMX1A promoter at −133/
+1 bp (Sp1-1, 2 binding sites) in Huh7 cells with or without Sp1
overexpression (Supplementary Fig. S5B). Taken together, these results
demonstrate that Sp1 binds directly to the LMX1A promoter and acti-
vates endogenous LMX1A expression when the LMX1A promoter is
unmethylated.
3.5. Knockdown of EZH2 decreases the level of H3K27me3 but does not
restore LMX1A in cervical cancer cell lines
The data presented above indicate that both DNA methylation and
histone (H3K27me3) modiﬁcation are involved in the silencing of the
LMX1A promoter (Fig. 4C). In addition, we found that overexpression
of EZH2 could decrease the LMX1A expression in theHuh7 cells (Supple-
mentary Fig. S6A). To further check whether H3K27me3, an EZH2-
speciﬁc chromatin repressive marker, participates in the regulation of
LMX1A, we used shRNAs to knockdown EZH2 in cervical cancer cells.
The results of qRT-PCR and Western blot analysis conﬁrmed the signif-
icant decrease in the EZH2 mRNA and the protein levels of EZH2 and
H3K27me3 in EZH2-knockdown cells (Fig. 5A). As a control, we used
CDH1, which is known to be regulated by EZH2-mediated silencing
[28]. The results of the ChIP–PCR analysis conﬁrmed that the knock-
down of EZH2 decreased the content of H3K27me3 histone marker inthe LMX1A and CDH1 promoters (Fig. 5B and Supplementary Fig. S6B).
The level of another chromatin repressive marker H3K9me3 was not
changed in the LMX1A and CDH1 promoters after EZH2 knockdown
(Fig. 5B and Supplementary Fig. S6B). However, EZH2 knockdown did
not restore the expression of LMX1A in HeLa3rd cells (Fig. 5C), but in-
crease CDH1 expression (Supplementary Fig. S6C). Previous studies
have shown that knockdown of EZH2 does not restore gene expression
or change the DNA methylation state [42,43], and those authors sug-
gested that other signaling was needed to induce promoter demethyla-
tion and reexpression of genes. We used bisulﬁte sequencing to assess
the methylation level of the LMX1A promoter in EZH2-knockdown
cells and found no signiﬁcant change in the DNA methylation level
(Fig. 5D and Supplementary Fig. S6D). And the ChIP–PCR results demon-
strated that the binding of DNMT1 was not different in EZH2-
knockdown cells and control cells (Fig. 5E). These data show that knock-
down of EZH2 decreases the H3K27me3 histone modiﬁcation but not
the methylation level of the promoter and that knockdown of EZH2 is
not sufﬁcient to restore LMX1A expression.
3.6. Suppression of EZH2may delay resilencing of LMX1A after the removal
of DNMT and HDAC inhibitors
It has been reported that knockdown of EZH2 is not sufﬁcient to re-
store RUNX3 expression in colorectal cancer (CRC) [43], and that EZH2
has limited roles in the RUNX3 promoter with dense methylation [43].
We therefore proposed that EZH2 might have some role in the regula-
tion of LMX1A promoter with low methylation. First, we checked
whether knockdown of EZH2 would change LMX1A-p−133/+221 re-
porter activity. Downregulation of EZH2 signiﬁcantly increased the pro-
moter activity of the LMX1A-p−133/+221 reporter comparedwith the
control (Fig. S7A and S7B). Inhibition of Sp1 by the Sp1 inhibitor (MTM)
or shRNA-Sp1 in EZH2-knockdown cells repressed exogenous LMX1A
promoter activity (Fig. S7A and S7B). These data suggested that both
EZH2 and Sp1 were involved in regulation of the LMX1A promoter
with lowmethylation. To further explore the role of EZH2 in the endog-
enous LMX1A promoter, we treated EZH2-knockdown cells with 5-aza-
dC and trichostatin A (TSA), and then depleted the cells of drugs for
3 days. During this process, mRNA expression of LMX1A was
reexpressed after treatment with 5-aza-dC and TSA, but LMX1A expres-
sionwas resilenced after the removal of these drugs for 3 days (Fig. 6A).
However, the expression level of LMX1Awasmaintained 3 days after re-
moval of the drugs in EZH2-knockdown cells but not in control cells
(Fig. 6A). Knockdown of EZH2 signiﬁcantly suppressed the resilencing
of LMX1A after removal of the drugs (Fig. 6A). The results of ChIP–PCR
analysis conﬁrmed that the H3K14 acetylation (H3K14ac) and Sp1
binding levels increased in the LMX1A promoter in cells treated with
5-aza-dC and TSA. Sp1 bindingwas signiﬁcantly higher after drug treat-
ment in EZH2-knockdown cells than in control cells (Fig. 6B). After re-
moval of the drugs for 3 days, LMX1A mRNA was still expressed and
the activation histonemarker H3K14acwas enriched in the LMX1A pro-
moter in EZH2-knockdown cells (Fig. 6B). The binding level of DNMT1
and H3K27me3 in the LMX1A promoter was signiﬁcantly lower in
EZH2-knockdown cells than in control cells after removal of the drugs
for 3 days (Fig. 6B). The binding of DNMT3B was similar to IgG control
in EZH2-knockdown cells and control cells at all time points (Fig. S8).
These results suggest that knockdown-EZH2may delay the resilencing
of LMX1A through modiﬁcation of chromatin status.
4. Discussion
Our study provides the ﬁrst evidence of the regulation of LMX1A in
cervical cancer.We found that Sp1 increased the LMX1Apromoter activity
and its expression during treatment of cervical cancer cells with demeth-
ylation agents. Suppression of EZH2 may delay resilencing of LMX1A
after the removal of DNMT and HDAC inhibitors. These data suggest
that Sp1 activates LMX1A expression upon oncogenic stress during the
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sive cancer, LMX1A is epigenetically silenced through histonemodiﬁca-
tion by EZH2 and DNA methylation by DNMTs. These data provide an
explanation for why the LMX1A and Sp1 protein expression patterns
are induced in CIN and are overexpressed in CIS. The biological signiﬁ-
cance of LMX1A modulation by Sp1 is supported by the ﬁnding that
Sp1–LMX1A regulation is abolished by promoter hypermethylation in
invasive SCC cells.
Sp1 can recruit chromatin remodeling complexes, such as switch/
sucrose nonfermentable (SWI/SNF) family proteins, to remodel chro-
matin structure and attract other cofactors such as p300 or CBP, which
activate transcription. Sp1 can also recruit repressor complexes, such
as the Sin3A HDAC1/HDAC2 complex, to repress gene transcription
[34]. Sp1 target genes include oncogenes, tumor suppressor genes,
and pro- and antiangiogenic factors involved in invasion, metastasis,
proliferation, oncogenesis, and antitumor activities. Sp1 expression
levels are higher in several human cancers associated with cellular
transformation [34–37]. By contrast, overexpression of Sp1 rescues the
expression of tumor suppressor genes and inhibits invasion and metas-
tasis [41,44].We found that Sp1 increased LMX1A promoter activity and
that this increase was abolished by introducing mutant Sp1 binding el-
ements into the LMX1A proximal promoter. LMX1A expression was re-
stored in cervical cancer cells after cells were treated with 5-aza-dC,
but this phenomenon was counteracted by inhibition of Sp1 in cervical
cancer cell lines. The LMX1A proximal promoter (LMX1A-p−133/
+221) has two Sp1 binding elements, which are hypermethylated in
cervical cancer. Methylated Sp1 binding elements of some genes
might impair Sp1 binding to their promoters [45,46].
The ChIP–PCR assay showed that the histone markers H3K14ac and
Sp1were enriched in the LMX1A promoter in cervical cancer cells treat-
edwith 5-aza-dC and TSA. These data imply that Sp1 recruits chromatin
remodeling complexes to the LMX1A promoter and thereby activates its
expression. In our study, the Sp1 protein expression patternwas similar
to that of LMX1A in cervical cancer. Sp1 has been reported to suppress
cancer invasion and metastasis through upregulation of CDH1 [40,41].
Our data suggest that Sp1 can inhibit cervical cancer metastasis partly
through LMX1A and that hypermethylation of the LMX1A promoter dis-
rupts this protective mechanism.
In our study, reexpression of tumor suppressor genes, as shown by
DNA demethylation and histone code alteration,was observed in cancer
cells treated with 5-aza-dC. Several reports have shown that the DNMT
inhibitor 5-aza-dC reduces the level of H3K27me3 and H3K9me3 in the
promoters of the target genes and induces their reexpression [47,48].
However, some reports have found no changes in H3K27me3 and
H3K9me3 levels in the promoter of these reexpressed genes in cells
treated with 5-aza-dC, but increased levels of H3K9/14ac, H3K4me2,
and H3K4me3 [49,50]. In our study, the histone code H3K27me3
seemed not to interfere with the transcriptional reactivation of LMX1A.
These data suggest that the repressive code H3K27me3 serves as an an-
chor for subsequent resilencingmodiﬁcation after removal of 5-aza-dC.
HPV E6 and E7 are important oncoproteins in cervical cancer carci-
nogenesis. HPV-16 E6 may upregulate DNMT1 through repression of
tumor suppressor p53 to regulate the development of cervical cancer
[25]. Previous reports showed that EZH2 expression is induced by E2F
at the transcriptional level through HPV-E7-mediated release of E2F
from pRB–E2F complex [26,51]. Moreover, methylation of histone
H3K27 acts mainly through EZH2, which is thought to be a potent re-
pressive marker associated with heterochromatic regions and gene si-
lencing [29]. EZH2 possesses HMT activity and is signiﬁcantly
upregulated in cervical cancer tissues and cell lines [26,27]. EZH2 knock-
down could not inﬂuence DNA methylation and reexpression of the
LMX1A gene in cervical cancer cells but may cause loss of H3K27me3
in the LMX1A promoter. These results are similar to those of reports
on other genes such as RUNX3, hMLH1, p16INK4a, MYT1, and WNT1
[42,43]. And EZH2 knockdown could decrease DNMT1 binding to the
LMX1A promoter after the removal DNMT and HDAC inhibitors for3 days. Our ﬁndings imply that EZH2 might play a limited role after
the establishment of promoter hypermethylation of LMX1A. Further-
more, Snail1 transcription factor could recruit PRC2 complex (EZH2
and SUZ12) to the E-box elements of CDH1 promoter and repress the
CDH1 expression [28]. Using the TFSEARCH website, we discovered six
putative E-box (CANNTG) binding sites in the promoter of LMX1A
gene and two of them located close to the TSS (Fig. 1A). These two con-
sensus E-box binding sites are E2 (−43/−38 bp) and E1 (−4/+2 bp)
in the LMX1A-p−133/+221 promoter. Put together, these data imply
that SNAIL1 might recruit EZH2 to the E-box of LMX1A promoter. How-
ever, it needs more experiments to prove.
After cell treatmentwith a demethylating agent and HDAC inhibitor,
Sp1 was enriched signiﬁcantly more in EZH2-knockdown cells com-
pared with control cells. After removal of the drug for 3 days, Sp1 did
not appear to be enriched in the LMX1A promoter. However, the level
of H3K14ac (active code) in the LMX1A promoter was still increased
and LMX1A mRNA was expressed in EZH2-knockdown cells even
3 days after removal of the drug. A previous study showed that Sp1 in-
teracts with coactivators such as p300 and CBP in cells treated with
demethylating agents and/or HDAC inhibitors [52]. Sp1 can cooperate
with GATA to increase erythroid gene expression [53]. Sp1 or GATA
might interact with HDACs to form a repressor complex that suppresses
gene expression individually [54,55]. There is one predicted GATA bind-
ing element in the LMX1A promoter (+71/+80) region near the Sp1
binding site. Therefore, we suggest that, in cells treated with a
demethylating agent and HDAC inhibitor, Sp1 recruits GATA, p300 or
CBP protein to form a transactivator complex. The chromatin region of
LMX1A might remain relaxed, which would allow Sp1 to associate
with coactivators to maintain gene expression after removal of the
drugs in EZH2-knockdown cells.
In summary, we demonstrate that Sp1 binds directly to the LMX1A
promoter and activates LMX1A expression. Knockdown of EZH2 can de-
crease H3K27me3 histone modiﬁcation but is insufﬁcient to restore
LMX1A expression. Our data suggest that Sp1 may activate LMX1A ex-
pression upon oncogenic stress during cervical cancer development. In-
hibition of EZH2 may increase H3K14ac level in the LMX1A promoter
and delay the time of LMX1A resilencing after removal of demethylating
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